CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSPATENTSPUBLICATIONSEdith M. Lord, Ph.D.Contact InformationPhone NumbersOffice: (585) 275-5855Research LabsVisit Lab WebsiteLocationsUniversity of Rochester Medical CenterSchool of Medicine and Dentistry601 Elmwood Ave, Box 316Rochester, NY 14642Faculty AppointmentsProfessor - Department of Microbiology and Immunology (SMD) Professor - Cancer Center - JointBiographyProfessional BackgroundDr. Edith Lord is a Professor of Microbiology & Immunology and Oncology. Dr. Lord received her BA degree in microbiology from the University of Kansas in 1970 and a Ph.D degree in immunology from the University of California at San Diego in 1975. She was a postdoctoral fellow at the University of California at San Francisco. As a faculty member since 1976, Dr. Lord has demonstrated excellence as a scientist and dedication to the training of graduate students and postdoctoral fellows. From 2006-2008, Dr. Lord led the graduate program in the Department of Microbiology and Immunology. She was the Senior Associate Dean for Graduate Education and Postdoctoral Affairs at the School of Medicine and Dentistry from 2008-2018. In her research, Dr. Lord focuses on the immune responses that can control tumor development and how immune cells function within the unique microenvironment of growing tumors. She has published, as author and co-author, more than 130 scientific articles and continues her passion for research today.CredentialsEducation1970BA | University of KansasMicrobiology1975PhD | Univ of Cal San DiegoImmunologyAwards2018Graduate Student Society Advocacy AwardPatentsPatent Title: Serum Free Cell Culture Medium Patent #: 4,816,401 Issue Date: Mar 28, 1989 Country: United States Invented By: Edith M LordPatent Title: Monoclonal Antibodies Differentially Reactive with Native and Reductively Modified Bowman-Birk Protease Inhibitor Patent #: 5,616,492 Issue Date: Apr 01, 1997 Country: United States Invented By: Ann R Kennedy, Cameron J Koch, Edith M Lord, Xingsheng WanPatent Title: Method of Monitoring Exposure to Bowman Birk Inhibitor Using Monoclonal Antibodies Against Bowman Birk Inhibitor Metabolites Patent #: 5,618,679 Issue Date: Apr 08, 1997 Country: United States Invented By: Ann R Kennedy, Cameron J Koch, Edith M Lord, Xingsheng WanPatent Title: Detection of Hypoxia with Reagents Containing 2-Nitroimidazole Compounds and Methods of Making such Reagents. Patent #: 5,540,908 Issue Date: Jul 30, 1996 Country: United States Invented By: Cameron J Koch, Edith M LordPatent Title: Detection of Hypoxia Patent #: 5,843,404 Issue Date: Dec 01, 1998 Country: United States Invented By: Cameron J Koch, Edith M LordVIEW ALL expand_morePublicationsJournal Articles4/25/2019"Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation." Radiation research.. 2019 Apr 25; Epub 2019 Apr 25. 12/27/2016Connolly KA, Belt BA, Figueroa NM, Murthy A, Patel A, Kim M, Lord EM, Linehan DC, Gerber SA. "Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes." Oncotarget.. 2016 Dec 27; 7(52):86522-86535. 11/2016Barlow ML, Cummings RJ, Pentland AP, Love TM, Haidaris CG, Ryan JL, Lord EM, Gerber SA. "Total-Body Irradiation Exacerbates Dissemination of Cutaneous Candida Albicans Infection." Radiation research.. 2016 Nov; 186(5):436-446. Epub 2016 Oct 06. VIEW ALL PUBLICATIONSClose WindowSchedule an appointmentPlease answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 3 years?YesNoExisting PatientSchedule or request an appointment online through MyChart.Who is the appointment for?Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.